Most NPC patients present with IgA antibodies to EBV viral capsid antigen (EBV-VCA) and EBV nuclear antigen 1 (EBNA1), and previous studies have shown that such IgA responses often precede tumor presentation by several years [32]. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.